SCHEMBL30411352

SCHEMBL30411352

CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2c1ccc([N+](=O)[O-])c(C2CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.45
▸ GPR119 Q8TDV5 9/20 0.43
▸ PARP1 P09874 1/20 0.40
▸ F13A1 P00488 1/20 0.40
▸ TGM2 P21980 1/20 0.40
▸ TGM1 P22735 1/20 0.40
▸ HDAC1 Q13547 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ RET P07949 2/20 0.37
▸ IDH1 O75874 1/20 0.37
▸ CCR2 P41597 1/20 0.36
▸ AR P10275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL30412048 0.97 HSD11B1 (0.43) HSD11B1GPR119PARP1F13A1TGM2
SCHEMBL30411472 0.86 HSD11B1 (0.46) HSD11B1GPR119PARP1F13A1TGM2
SCHEMBL30635739 0.86 HSD11B1 (0.46) HSD11B1GPR119PARP1F13A1TGM2
SCHEMBL25208776 0.84 AKR1C3 (0.35) MAPTALDH1A1CCR2
SCHEMBL30412220 0.84 HDAC1 (0.47) HSD11B1GPR119PARP1F13A1TGM2
SCHEMBL30410945 0.84 HDAC1 (0.47) HSD11B1GPR119PARP1F13A1TGM2
SCHEMBL30126003 0.83 RET (0.45) HSD11B1GPR119PARP1F13A1TGM2
SCHEMBL30635735 0.83 F13A1 (0.45) HSD11B1GPR119PARP1F13A1TGM2
SCHEMBL30411911 0.83 F13A1 (0.45) HSD11B1GPR119PARP1F13A1TGM2
SCHEMBL11920568 0.83 HSD11B1 (0.43) HSD11B1GPR119PARP1F13A1TGM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 — — US disclosed
EP-4433059-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Erasca, Inc. (US) 2024-09-25 — — EP disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 HSD11B1 3894/4885GPR119 3299/4885PARP1 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback